These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 31484664)

  • 1. The therapy of idiopathic pulmonary fibrosis: what is next?
    Somogyi V; Chaudhuri N; Torrisi SE; Kahn N; Müller V; Kreuter M
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31484664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.
    Aono Y; Nakamura Y; Kono M; Nakamura H; Yokomura K; Imokawa S; Toyoshima M; Yasui H; Hozumi H; Karayama M; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    Ther Adv Respir Dis; 2020; 14():1753466620953783. PubMed ID: 32928050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiopathic Pulmonary Fibrosis Among Young Patients: Challenges in Diagnosis and Management.
    Leuschner G; Reiter F; Stocker F; Crispin A; Kneidinger N; Veit T; Klenner F; Ceelen F; Zimmermann G; Leuchte H; Reu S; Dinkel J; Behr J; Neurohr C
    Lung; 2018 Aug; 196(4):401-408. PubMed ID: 29761229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe idiopathic pulmonary fibrosis: what can be done?
    Caminati A; Cassandro R; Torre O; Harari S
    Eur Respir Rev; 2017 Sep; 26(145):. PubMed ID: 28954763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential.
    Raghu G
    Eur Respir Rev; 2017 Sep; 26(145):. PubMed ID: 28954769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.
    Azuma A
    Expert Rev Respir Med; 2010 Jun; 4(3):301-10. PubMed ID: 20524912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.
    Collins BF; Raghu G
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31578210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?
    Costabel U
    Eur Respir Rev; 2011 Sep; 20(121):201-7. PubMed ID: 21881148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current approaches to the management of idiopathic pulmonary fibrosis.
    Raghu G; Richeldi L
    Respir Med; 2017 Aug; 129():24-30. PubMed ID: 28732832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
    Belhassen M; Dalon F; Nolin M; Van Ganse E
    Respir Res; 2021 May; 22(1):135. PubMed ID: 33947414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrosing interstitial lung diseases: knowns and unknowns.
    Cottin V; Wollin L; Fischer A; Quaresma M; Stowasser S; Harari S
    Eur Respir Rev; 2019 Mar; 28(151):. PubMed ID: 30814139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe idiopathic pulmonary fibrosis: A clinical approach.
    Lipsi R; Mazzola D; Caminati A; Elia D; Lonati C; Harari S
    Eur J Intern Med; 2018 Apr; 50():20-27. PubMed ID: 29361476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic advances in idiopathic pulmonary fibrosis.
    Fraser E; Hoyles RK
    Clin Med (Lond); 2016 Feb; 16(1):42-51. PubMed ID: 26833513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health economic evaluation in idiopathic pulmonary fibrosis in France.
    Porte F; Cottin V; Catella L; Luciani L; Le Lay K; Bénard S
    Curr Med Res Opin; 2018 Oct; 34(10):1731-1740. PubMed ID: 29368948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
    Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current challenges in the diagnosis and management of idiopathic pulmonary fibrosis in Japan.
    Bando M; Chiba H; Miyazaki Y; Suda T
    Respir Investig; 2024 Sep; 62(5):785-793. PubMed ID: 38996779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives.
    Kreuter M; Bonella F; Wijsenbeek M; Maher TM; Spagnolo P
    Biomed Res Int; 2015; 2015():329481. PubMed ID: 26779535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.